Kit for identifying malignancy, and uses thereof
AssigneeAgency for Science, Technology and Research
InventorsBong Hwa GAN, Masafumi INOUE, Veronica DIERMAYR
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a multiplexed amplification reaction kit for identifying a subject suffering from a malignancy sensitive to treatment with an inhibitor of the Wnt signaling pathway, comprising a primer pair capable of amplifying a PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion. Also disclosed is a method of identifying sensitivity to an inhibitor of Wnt signaling in a subject suffering from a malignancy, comprising detecting the PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion with a primer pair.
Claims16
1-30. (canceled)
A method of treating a malignancy in a subject, comprising:
- amplifying nucleic acids extracted from a sample from the subject with a primer pair capable of amplifying a PTPRK(e13)-RSPO3(e2) gene-fusion, and
- treating the malignancy in the subject when the PTPRK(e13)-RSPO3(e2) gene fusion is detected.
A method of identifying sensitivity to an inhibitor of Wnt signaling in a subject suffering from a malignancy and treating the subject, comprising:
- amplifying nucleic acid extracted from a sample from the subject with a primer pair capable of amplifying a PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion,
- identifying sensitivity to an inhibitor of Wnt signaling when a PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion is amplified, and
- treating the subject identified to be sensitive to an inhibitor of Wnt signaling.
A composition comprising:
- a biological sample comprising RNA obtained from a tumor tissue, and
- a primer pair capable of amplifying a PTPRK(e13)-RSPO3(e2) R-Spondin gene-fusion.
Dependencies are inferred from the claim text.